Is levocetirizine safe to use during pregnancy for allergic rhinitis or urticaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levocetirizine Safety in Pregnancy

Levocetirizine should be avoided during the first trimester of pregnancy due to limited safety data; if an antihistamine is necessary, use cetirizine, loratadine, or chlorphenamine instead, which have well-established safety profiles.

Evidence Quality and Limitations

The most significant limitation with levocetirizine is the lack of adequate human pregnancy data, particularly for first-trimester exposure 1. The American Academy of Allergy, Asthma, and Immunology explicitly recommends avoiding levocetirizine during the first trimester if possible 2, 3. This stands in contrast to its parent compound cetirizine, which has extensive safety data.

Preferred Antihistamine Alternatives

When antihistamine treatment is necessary during pregnancy, the following options have superior safety documentation:

  • Cetirizine (FDA Pregnancy Category B) has the most robust safety data, with multiple prospective cohort studies showing no increased risk of major malformations 4, 5, 6
  • Loratadine (FDA Pregnancy Category B) has accumulated substantial safety evidence and is preferred over levocetirizine 2, 3
  • Chlorphenamine is often chosen by clinicians due to its long-established safety record, though it is a first-generation antihistamine with sedating properties 2, 3

The key distinction is that while second-generation antihistamines as a class generally have excellent safety records 1, levocetirizine specifically lacks the epidemiologic studies that exist for cetirizine and loratadine.

Treatment Algorithm for Allergic Rhinitis/Urticaria in Pregnancy

First-line approaches:

  • Intranasal corticosteroids (preferably budesonide) may be used with favorable safety profiles, as systemic exposure is much lower than oral corticosteroids 1
  • Sodium cromolyn nasal spray (Pregnancy Category B) is considered safe, though requires four-times-daily dosing which limits patient acceptance 1

If oral antihistamine is required:

  • Use cetirizine or loratadine as first choice due to extensive safety data 2, 3
  • Chlorphenamine is an alternative if second-generation agents are not tolerated 2
  • Avoid levocetirizine, particularly in the first trimester 2, 3

Medications to avoid:

  • Oral decongestants (phenylephrine, pseudoephedrine) should be avoided during the first trimester due to conflicting reports of gastroschisis and small intestinal atresia 1
  • Hydroxyzine should be avoided during the first trimester based on concerning animal data 1
  • Combining decongestants with acetaminophen or salicylates increases malformation risk 1

Critical Timing Considerations

The first trimester is the highest-risk period for medication-induced congenital malformations due to organogenesis 2. While both first- and second-generation antihistamines generally show no significant increase in congenital malformations when used during this period 1, the specific lack of data for levocetirizine makes it a less prudent choice when alternatives with established safety exist.

Common Pitfalls to Avoid

  • Do not assume all antihistamines have equivalent safety profiles during pregnancy—they do not, and the quality of available data varies significantly 2, 3
  • Do not use levocetirizine simply because it is the "active enantiomer" of cetirizine—the parent compound cetirizine has far superior pregnancy safety documentation 4, 5, 6
  • Avoid the temptation to use oral decongestants for nasal congestion during the first trimester; topical decongestants for short-term use or intranasal corticosteroids are safer alternatives 1

Risk-Benefit Assessment

While the benefit of symptom relief must be weighed against potential fetal risks 2, the availability of well-studied alternatives (cetirizine, loratadine, intranasal corticosteroids) makes it difficult to justify levocetirizine use when safer options exist. The lack of epidemiologic studies for levocetirizine 1 means we cannot confidently state it is safe, even though theoretical concerns may be low.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Safety of Levocetirizine During First Trimester of Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Safety of Levocetirizine and Montelukast During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Safety of cetirizine in pregnancy.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2018

Research

The fetal safety of cetirizine: an observational cohort study and meta-analysis.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.